|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HOPX is involved in multiple organ development and acts as a tumor suppressor in various cancers.
|
31666923 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, HOPX acts as a tumour suppressor via the epigenetic regulation of SNAIL transcription, which provides a novel prognostic biomarker for NPC metastasis and therapeutic target for NPC treatment.
|
28146149 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HOPX is thought as a tumor suppressor gene and its promoter methylation is the main mechanism of down-regulation.
|
27756570 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate that applying INSPIRE to nine ovarian cancer datasets leads to a new marker and potential driver of tumor-associated stroma, HOPX, followed by experimental validation.
|
27287041 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results demonstrate that HOPX functions as a tumour suppressor in HNSCC and suggest a central role for HOPX in suppressing epithelial carcinogenesis.
|
27934959 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It turned out that HOPX inhibited tumour cell proliferation rate, migration, and invasion, and, more interestingly, forced expression of HOPX enhanced cellular senescence via activation of oncogenic Ras and the downstream MAPK pathway, which in turn led to decreased MDM2 and increased p21.
|
25345926 |
2015 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
PC tissues had HOPX gene hypermethylation as compared to the corresponding normal pancreas tissues, and its uniqueness was robust to discriminate tumor from normal tissues (AUC = 0.85, P < 0.0001).
|
22958219 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Decreased expression of CHIP in proliferating cancer cells is in keeping with its proposed tumor suppressor properties, while over-expression of HOP in proliferating cells may contribute to excessive Hsp90 activity and stabilization of client proteins in tumors.
|
22669480 |
2012 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer.
|
20228841 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HOPX (homeodomain only protein X) is a newly identified homeobox gene whose loss of expression has been reported for several types of neoplasm.
|
19173292 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, HOP is a putative TSG that harbors tumor inhibitory activity, and we for the first time showed that the final shutdown process of HOP expression is linked to promoter DNA hypermethylation under the double control of the discrete promoter regions in cancer.
|
18234960 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, HOP may work as a tumor suppressor in a subset of glioblastomas.
|
18507846 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HOP positive transfectants remarkably reduced the growth rate and the ability of anchorage-independent growth in soft agar, and moreover suppressed the tumor formation in nude mice compared to controls.
|
17417779 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, HOP has very recently been shown to be a tumour suppressor involved in differentiation, suggesting that HOP may have a similar role in head and neck squamous cell carcinoma (HNSSC).
|
15213722 |
2004 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HOP mRNA and protein levels were significantly higher in GC tissues than in normal tissues in our medical center (P< 0.001) and in The Cancer Genome Atlas database (P< 0.001).
|
29843139 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.
|
27756570 |
2017 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We also demonstrate that primary human cancers contain high levels of phosphorylated chaperones and show increased levels of HOP protein and mRNA.
|
22824801 |
2013 |
|
Malignant Neoplasms
|
0.060 |
PosttranslationalModification
|
group |
BEFREE |
Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis.
|
22958219 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer.
|
22669480 |
2012 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
In conclusion, HOP is a putative TSG that harbors tumor inhibitory activity, and we for the first time showed that the final shutdown process of HOP expression is linked to promoter DNA hypermethylation under the double control of the discrete promoter regions in cancer.
|
18234960 |
2008 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
HOP mRNA and protein levels were significantly higher in GC tissues than in normal tissues in our medical center (P< 0.001) and in The Cancer Genome Atlas database (P< 0.001).
|
29843139 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.
|
27756570 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer.
|
22669480 |
2012 |
|
Primary malignant neoplasm
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis.
|
22958219 |
2012 |